Vical Receives New Patent By: MarketMinute.com Stock News September 03, 2009 at 14:16 PM EDT Vical Inc. (Nasdaq: VICL) received a new patent for its Vaxfectin-formulated DNA vaccines for seasonal and pandemic flu viruses. The stock price climbed 52 cents to $4.93.